OncoMatch/Clinical Trials/NCT06361888
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Is NCT06361888 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies multiple treatments including Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine and Nab-paclitaxel Plus Gemcitabine for metastatic pancreatic cancer.
Treatment: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine · Nab-paclitaxel Plus Gemcitabine · Surufatinib with Nab-paclitaxel, and Gemcitabine — To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anticancer therapy for metastatic pancreatic cancer
Have not received previous systematic first line anti-tumor treatment in the stage of metastatic pancreatic cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06361888 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for metastatic pancreatic cancer disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages